{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:44:35Z","timestamp":1767602675157,"version":"3.48.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtha.2025.09.017","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:38:01Z","timestamp":1767602281000},"page":"337-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cThromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post hoc analysis of BENEFIT\u201d: comment from Galarza Fortuna et al."],"prefix":"10.1016","volume":"24","author":[{"given":"Gliceida M.","family":"Galarza Fortuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian J.","family":"Rahbari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.017_bib1","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.jtha.2025.06.012","article-title":"Thromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post-hoc analysis of BENEFIT trial","volume":"23","author":"Chalayer","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.017_bib2","first-page":"94","volume":"3","author":"Trousseau","year":"1865"},{"key":"10.1016\/j.jtha.2025.09.017_bib3","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.017_bib4","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.017_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","article-title":"The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2025.09.017_bib6","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.09.017_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6004\/jnccn.2021.7112","article-title":"Optimizing thromboembolism prophylaxis for the contemporary age of multiple myeloma","volume":"20","author":"Baljevic","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtha.2025.09.017_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtha.2025.09.017_bib9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.09.017_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.18630","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","volume":"201","author":"Dima","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.09.017_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br J Haematol"},{"issue":"16 suppl","key":"10.1016\/j.jtha.2025.09.017_bib12","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1200\/JCO.2025.43.16_suppl.7561","article-title":"Real-world analysis of thromboembolism in SAVED\/IMPEDE risk-stratified newly diagnosed multiple myeloma (NDMM)","volume":"43","author":"Rahbari","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.09.017_bib13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.017_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.jtha.2025.09.017_bib15","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1182\/blood-2023-190746","article-title":"High rates of thrombotic events in newly diagnosed multiple myeloma patients enrolled on the MAIA trial","volume":"142","author":"Rosqvist","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.017_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:41:28Z","timestamp":1767602488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538783625006087"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cThromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post hoc analysis of BENEFIT\u201d: comment from Galarza Fortuna et al.","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}